MUMBAI, 8 JANUARY, 2023 (GPN): Pathkind Diagnostics, one of the largest pathology chains in the country is all set to transform diabetes care in India with Roche Diagnostics’ cardiac biomarker- NTProBNP that is used in the management of Type 2 Diabetes (T2DM). NTProBNP is the gold-standard biomarker for detecting heart failure in patients and Roche Diagnostics is the only company to have received a claim extension allowing it to be used for identification of the risk of heart failure and other cardiovascular risks in people living with T2DM. With the incorporation of NTProBNP in diabetes management, Pathkind will be a leader in providing comprehensive and holistic diabetes and cardiac care.

Speaking on the occasion, Sanjeev Vashishta, MD & CEO Pathkind Labs said, “We are pleased to collaborate with Roche Diagnostics to further advance the treatment of diabetes and cardiovascular disease. Diabetes patients must receive a prompt diagnosis of heart disease in order to manage their health to the best of their ability. The co-existence of diabetes mellitus and heart failure has significant clinical and economic implications in terms of clinical visits, hospital admissions, quality of life, morbidity, and mortality. The addition of this high-sensitivity NTProBNP test will assist healthcare professionals and patients in making important medical decisions. At Pathkind, our aim is to reach out the last man even in the tier 2/3 towns with our superior quality diagnostics offering and this collaboration with Roche will strengthen our foot print in these geographies as well.”

Narendra Varde, Managing Director, Roche Diagnostics India & Neighboring Markets, said “Today, modern technology and our evolving understanding of disease have given us newer options for personalizing therapy, reducing unnecessary expenses, and protecting those in need. Incorporating NTProBNP, a simple blood test, to help detect and monitor heart failure as part of diabetes treatment and management is critical and essential. In order to lower mortality and CVD events, it is crucial to screen people with T2DM for CVD risk, therefore our partnership with Pathkind will be a turning point in diabetes management.”

In India, presently a total of 107 million  adults have been diagnosed with T2DM. The prevalence of adults with pre-diabetes is much higher and is estimated to be 255 million 1. A study conducted by the Practice Innovation and Clinical Excellence (PINNACLE) India Quality Improvement Program (PIQIP) on the coexistence of T2DM and heart failure highlights that T2DM was coexistent in 23% of people with HF with reduced ejection fraction (HFrEF) 2. T2DM was a frequent comorbidity, observed in 55% of these hospitalized patients in the Trivandrum Heart-Failure Registry 2. Moreover, these studies also estimated that the annual incidence of heart failure in India is expected to increase by 18%. All the above evidence indicates that the growing burden of HF among T2DM patients requires urgent action.

According to Dr Aarti Khanna Nagpal, Pathkind Labs, “In diabetic heart failure patients, the value of NTProBNP holds a pivotal role in the evaluation of their overall status, facilitating the establishment of correct therapy management and follow-up. Evidence gathered so far highlights that NTProBNP is a direct predictor of adverse outcome and cardiovascular mortality, making this marker instrumental in the management of CVDs in T2D patients. With diabetes’ unrelenting growth, it is paramount for healthcare professionals to re-evaluate how they treat and manage a challenging patient population.” 

About Pathkind Labs

Pathkind Diagnostics is one of the leading diagnostic chains in India providing superior quality diagnostics services through an efficient network of labs and customer touch points spread across Tier 2, Tier 3 & 4 cities and towns over and above their strong presence in Metros & Tier 1 cities. Pathkind is founded by Mankind Pharma Promoters and Mr. Sanjeev Vashishta. One of the primary objectives of Pathkind Labs is to provide accurate results/ reports using state-of-the-art technologies in the least possible time (Quick Turn Around Time) at affordable price. In just 5 years of inception, Pathkind has created a robust network comprising of 80 labs, 2500 Collection Centres and over 5000 pick up points across 25 states in the country. It has over 1 Cr satisfied customers including hospitals, doctors and patients. Pathkind uses state-of-the-art technology including NGS, Sanger Sequencer on the Molecular Biology side, LCMS/ICPMS in Biochemistry, Flowcytometry in Hematology, strong coverage on IHC Histopathology and Luminex in HLA typing and Transplant immunology tests etc. Pathkind has highly qualified, motivated and skilled teams of doctors, scientists, technicians and other professionals.

For more information, please visit https://www.pathkindlabs.com/

About Roche Diagnostics India

Roche is the world’s largest biotech company. Roche Diagnostics India Pvt. Ltd. established in the year 2002 has offices located in Chennai, Delhi, Kolkata and Mumbai with over 400 employees. Our broad range of innovative diagnostic tests and systems play a pivotal role in the groundbreaking area of integrated healthcare solutions and cover early detection, targeted screening, evaluation and monitoring of disease. Roche Diagnostics India works with the objective of “Doing now what patients need next”, thus preparing for the nation’s future healthcare needs.Ends GPN SM